Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study

The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Toyohiro, Nakane, Keita, Enomoto, Torai, Tomioka, Masayuki, Taniguchi, Tomoki, Ishida, Takashi, Ozawa, Kaori, Takagi, Kimiaki, Ito, Hiroki, Takeuchi, Shinichi, Kawase, Makoto, Kawase, Kota, Kato, Daiki, Takai, Manabu, Iinuma, Koji, Yokoi, Shigeaki, Nakano, Masahiro, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/
https://www.ncbi.nlm.nih.gov/pubmed/36140344
http://dx.doi.org/10.3390/biomedicines10092243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/
https://www.ncbi.nlm.nih.gov/pubmed/36140344
http://dx.doi.org/10.3390/biomedicines10092243

Ejemplares similares